Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ERN1 | O75460 | 10/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29729025 | 0.87 | CA1 (0.59) | CA1CA2ALDH1A1ERN1TRIM24 | |
| SCHEMBL3345839 | 0.87 | CA1 (0.59) | CA1CA2ALDH1A1ERN1TRIM24 | |
| SCHEMBL31538163 | 0.86 | CA1 (0.47) | CA1CA2ALDH1A1ERN1TRIM24 | |
| SCHEMBL1238926 | 0.86 | CA1 (0.43) | CA1CA2ALDH1A1ERN1TRIM24 | |
| SCHEMBL3256940 | 0.82 | CA1 (0.41) | CA1CA2ALDH1A1ERN1TRIM24 | |
| SCHEMBL16411961 | 0.82 | CA1 (0.41) | CA1CA2ALDH1A1ERN1TRIM24 | |
| SCHEMBL16187926 | 0.82 | ERN1 (0.53) | CA1CA2ERN1TRIM24TYR | |
| SCHEMBL9894251 | 0.82 | ERN1 (0.53) | CA1CA2ERN1TRIM24TYR | |
| SCHEMBL680844 | 0.82 | CA1 (0.61) | CA1CA2ALDH1A1ERN1MCL1 | |
| SCHEMBL9873091 | 0.79 | KDM4E (0.43) | CA1CA2ALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184236-A1 | NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND | National Institutes for Quantum Science and Technology (JP) | 2022-06-16 | — | — | US | disclosed |
| US-20220089455-A1 | METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDED | ASTELLAS PHARMA INC. (JP) | 2022-03-24 | — | — | US | disclosed |
| EP-3904294-A1 | METHOD FOR PRODUCING NANOPARTICLES INCLUDING METAL PARTICLES CONTAINING IRON OXIDE HAVING AT LEAST ONE HYDROPHILIC LIGAND COORDINATED THERETO | Astellas Pharma Inc. (JP) | 2021-11-03 | — | — | EP | disclosed |
| EP-3904331-A1 | NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND | Astellas Pharma Inc. (JP) | 2021-11-03 | — | — | EP | disclosed |
| CN-113227040-A | Nanoparticles, nuclear magnetic resonance imaging contrast agent containing nanoparticles and zwitterionic ligand compound | 安斯泰来制药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| CN-113226990-A | Method for producing nanoparticles comprising iron oxide-containing metal particles to which one or more hydrophilic ligands are coordinately bound | 安斯泰来制药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| US-11008345-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008345-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| CN-108610356-B | Benzoxaborole derivatives for the treatment of bacterial infections | 阿纳科制药公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020138404-A1 | METHOD FOR PRODUCING NANOPARTICLES INCLUDING METAL PARTICLES CONTAINING IRON OXIDE HAVING AT LEAST ONE HYDROPHILIC LIGAND COORDINATED THERETO | アステラス製薬株式会社 | 2020-07-02 | — | — | WO | disclosed |
| CN-103140228-A | Benzoxaborole derivatives for the treatment of bacterial infections | ANACOR PHARMACEUTICALS INC | 2013-06-05 | — | — | CN | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012033858-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012033858-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| US-7091220-B2 | Substituted indole Mannich bases | GRUENENTHAL GMBH (DE) | 2006-08-15 | — | — | US | disclosed |
| CN-1219763-C | Substituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2005-09-21 | — | — | CN | disclosed |
| CN-1413192-A | Substituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2003-04-23 | — | — | CN | disclosed |
| US-20030060497-A1 | Subtituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060497-A1 | Subtituted indole mannich bases | TPH1, IDO1, TPH2 | CA1 2887/4885CA2 2406/4885ALDH1A1 667/4885 |
| US-20220089455-A1 | METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDED | FTH1, HAMP, TFRC | CA1 934/4885CA2 1788/4885ALDH1A1 2870/4885 |
| US-11008345-B2 | Boron-containing small molecules | BCL6B, BTD, BROX | CA1 4452/4885CA2 1021/4885ALDH1A1 4256/4885 |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | CA1 4452/4885CA2 1021/4885ALDH1A1 4256/4885 |
| US-20220184236-A1 | NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND | CD47, LPAR3, NMRAL1 | CA1 555/4885CA2 372/4885ALDH1A1 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.